Peptide Referee

CJC-1295 without DAC (Mod GRF 1-29): research, legal status and who sells it

This page is information, not medical advice. CJC-1295 without DAC (Mod GRF 1-29) is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.

Also known as
Modified GRF (1-29), Mod GRF 1-29, CJC-1295 no DAC
Category
Synthetic GHRH(1-29) analogue: CJC-1295 without its drug affinity complex (DAC)
Evidence level
Preclinical (lab and animal studies)
Price range
$2.50/mg to $21.48/mg, median $6.80/mg across 67 vendors (compare)
Our lab tests
None yet (how testing will work)
WhereStatus
United StatesNot FDA-approved; FDA's list of compounding safety risks names CJC-1295 without distinguishing forms with or without DAC, and that nomination was withdrawn [1][2].
United KingdomNo UK-licensed medicine containing CJC-1295 or modified GRF (1-29) appears in the MHRA products database [3][4].
European UnionNo medicine containing CJC-1295 or modified GRF (1-29) is authorized in the EU, according to EMA's central and Article 57 product data [5][6].
CanadaNo product containing CJC-1295 or modified GRF (1-29) appears in Health Canada's Drug Product Database [7].
AustraliaAustralia's Poisons Standard names CJC-1295 (CAS No. 863288-34-0) and lists growth hormone releasing hormones (GHRHs), both in Schedule 4 with Appendix D possession controls; it doesn't name the version without DAC separately [8].
Sport (WADA)Not named, but S2 prohibits growth hormone-releasing hormone (GHRH) and its analogues at all times, naming CJC-1293, CJC-1295, sermorelin and tesamorelin as examples [9].
 Summaries of official sources, checked —. Rules change; follow the source links. Not legal advice.

We haven't published a full overview of CJC-1295 without DAC (Mod GRF 1-29) yet. The legal status table and live prices on this page are current.

CJC-1295 without DAC (Mod GRF 1-29) compared

CJC-1295 without DAC (Mod GRF 1-29) prices: cheapest listings

The five lowest $/mg listings out of 91. See all CJC-1295 without DAC (Mod GRF 1-29) prices

Vendor Transparency Product Size Price $/mg vs median Stock Vendor's page
Bulk Peptide Supply 57/100* CJC-1295 NO DAC 10 mg 10 mg $25 $2.50/mg −63% In stock View
Bulk Peptide Wholesale 45/100* CJC-1295 NO DAC 10 MG (10 VIALS) 10 mg × 10 $250 $2.50/mg −63% In stock View
IDUN Peptides 50/100* CJC-1295 (No DAC) — Mod GRF 1-29 10 mg × 10 $260 $2.60/mg −62% Out of stock View
Panda Peptide 50/100* CJC-1295 (sans DAC) 10mg 10 mg CA$40 $2.81/mg* −59% In stock View
Iron Aminos 40/100* CJC-1295 NO DAC 10MG 10 mg × 10 $297 $2.97/mg −56% In stock View

Prices come from each vendor's public product feed and were last fetched Oct 15, 2026. They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. $/mg marked * was converted to US dollars from the listed currency at the European Central Bank reference rate. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.

Sources

  1. Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 15, 2026
  2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 15, 2026
  3. MHRA Products: licensed-medicine search for "cjc-1295". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 15, 2026
  4. MHRA Products: licensed-medicine search for "modified grf". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 15, 2026
  5. EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 15, 2026
  6. EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 15, 2026
  7. Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 15, 2026
  8. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 15, 2026
  9. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 15, 2026
  10. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology (2026). Accessed Oct 15, 2026
  11. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Testing and Analysis (2019). Accessed Oct 15, 2026